Richard I. Steinhart is CFO at BioXcel Therapeutics, Inc. (BTAI). They have made 7 open-market trades across 3 companies since 2010, most recently 2026-06-15.
CIK 0001293789
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $21K since 2010, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BTAI | SELL · 10b5-1 | 2026-05-20 | 2026-05-22 | $1.09 | $7K | +9.3% | +12.8% | -28.9% |
| BTAI | SELL · 10b5-1 | 2024-12-16 | 2024-12-17 | $0.36 | $208 | -6.0% | -11.4% | -63.5% |
| BTAI | SELL · 10b5-1 | 2024-10-03 | 2024-10-03 | $0.55 | $4K | +3.4% | +17.3% | -28.7% |
| BTAI | SELL · 10b5-1 | 2024-09-16 | 2024-09-17 | $0.69 | $246 | -5.8% | -10.9% | -36.5% |
| BTAI | SELL · 10b5-1 | 2024-06-17 | 2024-06-18 | $1.26 | $469 | -3.3% | +2.5% | -47.1% |
| BTAI | SELL · 10b5-1 | 2024-04-04 | 2024-04-08 | $2.64 | $3K | -1.2% | -17.8% | -58.1% |
| BTAI | SELL · 10b5-1 | 2023-05-15 | 2023-05-16 | $27.17 | $136K | -31.9% | -22.4% | -84.4% |
| BTAI | SELL · 10b5-1 | 2023-03-15 | 2023-03-16 | $19.50 | $41K | -7.4% | +12.3% | +11.3% |
| BTAI | SELL | 2021-02-01 | 2021-02-03 | $48.15 | $361K | +2.1% | -18.3% | -42.5% |
| BTAI | BUY | 2018-12-03 | 2018-12-04 | $5.20 | $3K | -24.8% | +1.2% | +79.8% |
| BTAI | BUY | 2018-11-30 | 2018-11-30 | $5.00 | $3K | -16.1% | -22.5% | +70.3% |
| BTAI | BUY | 2018-11-29 | 2018-11-30 | $5.00 | $3K | -16.1% | -22.5% | +70.3% |
| ATNM | BUY | 2016-04-14 | 2016-04-18 | $2.01 | $5K | -9.2% | -18.4% | -18.4% |
| MELA | BUY | 2013-06-25 | 2013-06-25 | $0.81 | $2K | N/A | N/A | N/A |
| MELA | BUY | 2010-08-12 | 2010-08-12 | $6.32 | $6K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.